| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net revenue | 32 | 2,889* | 260 | 518 |
| Cost of revenues | 17 | 1,317* | 121 | 168 |
| Cost of revenues amortization of acquired intangibles | NaN | 7* | 0 | 0 |
| Gross profit | 15 | 1,565* | 139 | 350 |
| Research and development | 4,953 | 16,112* | 3,878 | 3,281 |
| Sales and marketing | 2,402 | 2,074* | 1,386 | 1,460 |
| General and administrative | 2,991 | 2,845* | 2,545 | 2,647 |
| Impairment loss on held for sale assets | NaN | NaN | 0 | 0 |
| Change in fair value of contingent consideration | -5,918 | -3,327* | 3,378 | 2,804 |
| Impairment losses | NaN | 3,650* | NaN | NaN |
| Total operating expenses | 4,428 | 21,354* | 11,187 | 10,192 |
| Loss from operations | -4,413 | -19,789* | -11,048 | -9,842 |
| Interest expense | -23 | -28* | -29 | -25 |
| Other income, net | 146 | 489* | 223 | 125 |
| Total other income, net | 123 | 461* | 194 | 100 |
| Loss before income taxes | -4,290 | -19,328 | -10,854 | -9,742 |
| Income taxes | NaN | NaN | NaN | 0 |
| Net loss | -4,290 | -19,328 | -10,854 | -9,742 |
| Basic EPS | -0.12 | -0.706 | -0.34 | -0.3 |
| Diluted EPS | -0.12 | -0.706 | -0.34 | -0.3 |
| Basic Average Shares | 34,519,000 | 27,372,000 | 32,033,000 | 32,023,000 |
| Diluted Average Shares | 34,519,000 | 27,372,000 | 32,033,000 | 32,023,000 |
Insight Molecular Diagnostics Inc. (IMDX)
Insight Molecular Diagnostics Inc. (IMDX)